Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

A new pill for treating dementia is delivering promising "topline" results in early-stage clinical trials, according to a ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB. N ...

Lucid Capital analyst Elemer Piros initiated coverage of Passage Bio (PASG) with a Buy rating and $68 price target Passage Bio, which has ...